GLP1R and myocardial infarction: Intravenous (iv) administration of exenatide during the first 6 h after myocardial infarction has been shown to reduce infarct size [15–17], through a cardioprotective mechanism independent of the improvement of glycemic control [18], implying the activation of G protein—coupled GLP-1 receptor present in myocytes [19].